A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with primary osteoarthritis of the knee (FORWARD)

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with primary osteoarthritis of the knee (FORWARD)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Sprifermin (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Acronyms FORWARD
  • Sponsors EMD Serono
  • Most Recent Events

    • 16 Jun 2018 Results of a post-hoc analysis assessing structural Effects presented at the 19th Annual Congress of the European League Against Rheumatism
    • 08 Nov 2017 Results of two-year primary analysis data presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 04 Nov 2017 According to a Merck KGaA media release, Dr. Marc C. Hochberg, Division Head, Rheumatology and Clinical Immunology, University of Maryland School of Medicine is the primary investigator of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top